Company Overview
Company Type: Public Company
Website: www.criver.com
Number of Employees: 20,700
Ticker: CRL (NYSE)
Year Founded: 1947


Business Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Financial Information (Currency: CAD, in mm) 
Total Revenue
5,683.0
Market Capitalization
13,642.4
TEV/Total Revenue
3.1x
EBITDA
1,296.0
Total Enterprise Value
17,629.9
TEV/EBITDA
12.6x
EBIT
878.6
Cash & ST Invst.
272.6
P/Diluted EPS Before Extra
20.7x
Net Income
658.3
Total Debt
4,194.4
Price/Tang BV
NM
Capital Expenditure
(456.6)
Total Assets
10,571.4
Total Debt/EBITDA
3.0x
Currency in CAD in mm, LTM as of Jul-01-2023 TEV and Market Cap are calculated using a close price as of Oct-10-2023


Estimates & Guidance Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
EPS Normalized
3.22
3.22
14.36
14.01 - 14.83
14.27
Revenue (mm)
1,360.06
1,358.84 - 1,385.74
5,626.98
5,543.16 - 5,651.32
5,671.63
EBITDA (mm)
328.36
-
1,397.17
-
1,408.52

Forward Multiples (Current FY)

Price/Earnings
18.66x
TEV/REV
3.15x
TEV/EBITDA
12.70x
PEG
1.39x
P/BV
2.88x

Non-Periodic Estimates

Recommendation
Outperform (1.71)
Target Price
319.90
Potential Upside
19.34%
LT Growth (%)
13.46%


Key Professionals
Name
Title
Foster, James C.
Chairman, CEO & President
Pease, Flavia H.
Corporate Executive VP & CFO
Girshick, Birgit 
Corporate Executive VP & COO
Knell, Michael Gunnar
Corporate Senior VP & Chief Accounting Officer
Frearson, Julie 
Corporate Senior VP & Chief Scientific Officer
Mintz, Mark 
Corporate Senior VP & Chief Information Officer
Spencer, Todd 
Corporate Vice President of Investor Relations
Daniel, Matthew L.
Corporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer
Cianciaruso, Amy 
Corporate Vice President & Chief Communications Officer
Eisenhauer, Kristen M.
Corporate Senior Vice President of Client Services & Sales
LaPlume, Joseph W.
Corporate Executive Vice President of Corporate Development & Strategy
Mullane, Gina M.
Chief Marketing Officer & Corporate Senior VP

Key Board Members
Name
Title
Foster, James C.
Chairman, CEO & President
Kochevar, Deborah T.
Independent Director
Reese, C. Richard
Independent Director
Wallman, Richard F.
Independent Director
Wilson, Virginia Mary
Independent Director
Massaro, George E.
Lead Independent Director
Andrews, Nancy C.
Independent Director
Bertolini, Robert J.
Independent Director
Llado, George 
Independent Director
MacKay, Martin W.
Director
Thompson, Craig B.
Independent Director


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
251 Ballardvale Street | Wilmington, MA | 01887 | United States
Phone: 781 222 6000   

Current and Pending Investors
Carlisle Capital Corporation, JANA Partners LLC, Neuberger Berman BD LLC, People For The Ethical Treatment Of Animals, Inc., Warburg Pincus LLC

Prior Investors
1818 Mezzanine Fund II, L.P., 1818 Mezzanine Fund, L.P., Apriori Capital Partners L.P., BBH Capital Partners, Carlyle High Yield Partners, L.P., Credit Suisse Private Equity, LLC, DLJ Merchant Banking Partners II, L.P., New Leaf Venture Partners, LLC, Relational Investors LLC, Sprout Group, Sprout VIII, L.P., TCW Crescent Mezzanine II, TCW Investment Management Company LLC, TCW Leveraged Income Trust II L.P., TCW/Crescent Mezzanine Partners, L.L.C., The Carlyle Group Inc. (NasdaqGS:CG), Tinicum Incorporated

Investment Arms
Charles River Laboratories International Inc., Asset Management Arm

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 268.05
Market Cap (mm)
13,743.5
Open
 266.56
Shares Out. (mm)
51.3
Previous Close
 268.05
Float %
98.9%
Change on Day
1.97
Shares Sold Short (mm)
1.7
Change % on Day
0.7%
Dividend Yield %
-
Day High/Low
 268.50/ 264.06
Diluted EPS Excl. Extra Items
12.84
52 wk High/Low
 356.35/ 246.48
P/Diluted EPS Before Extra
20.88x
Volume (mm)
0.23
Avg 3M Dly Vlm (mm)
0.47
Beta 5Y
1.33


 
Delayed Quote** | Last Updated on Oct-11-2023 12:00 AM (GMT-5)
NYSE:CRL - Common Stock


Index Membership
S&P 500;S&P 500 Health Care (Sector);S&P Composite 1500;S&P 500 Value;S&P Global 1200;S&P 500 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P 500 Equal Weighted;S&P 500 - Life Sciences Tools & Services (Industry);S&P 500 - Life Sciences Tools & Services (Sub Ind);S&P 900 Value;S&P TMI Index;S&P Global 1200 Health Care Index;S&P 900;S&P Composite 1500 - Life Sciences Tools & Services (Industry);S&P Composite 1500 - Life Sciences Tools & Services (Sub Ind);S&P Composite 1500 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Composite 1500 Health Care (Sector);S&P Composite 1500 Value;S&P 500 EQUAL WEIGHTED Health Care (Sector);S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index;S&P 500 Dividend Index;S&P Americas BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas BMI Growth Index;S&P Americas SmallCap Health Care (Sector) Index;S&P Americas BMI Index;S&P Americas BMI Health Care (Sector) Index;S&P Americas SmallCap Index;S&P Developed BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas Over USD5 Billion Index;S&P Americas SmallCap Growth Index;S&P Americas SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P DM Ex-Australia SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific BMI Growth Health Care (Sector) Index;S&P Developed Ex-Europe BMI Growth Index;S&P Developed Ex-Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Health Care (Sector) Index;S&P Developed BMI Index;S&P Developed Ex-Asia-Pacific BMI Growth Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Eurozone BMI Growth Index;S&P Developed Ex-Eurozone SmallCap Index;S&P Developed Ex-Eurozone SmallCap Health Care (Sector) Index;S&P Developed BMI Growth Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P DM Ex-Asia-Pacific BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Europe BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Growth Index;S&P Developed Ex-Canada BMI Index;S&P Developed Ex-Canada BMI Health Care (Sector) Index;S&P Developed Ex-Canada BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Canada SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland SmallCap Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Australia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Europe SmallCap Index;S&P Developed Ex-Eurozone BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia BMI Growth Index;S&P Developed Ex-Australia BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P Developed Ex-Canada BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Health Care (Sector) Index;S&P Developed Ex-Canada SmallCap Health Care (Sector) Index;S&P Developed SmallCap Index;S&P Developed Ex-Eurozone Over USD5 Billion Index;S&P Developed Ex-Eurozone SmallCap Growth Index;S&P DM Ex-Eurozone SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Health Care (Sector) Index;S&P DM Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Canada BMI Growth Index;S&P DM Ex-Canada SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe BMI Index;S&P Developed Ex-U.K. Over USD5 Billion Index;S&P Developed Ex-U.K. SmallCap Index;S&P Developed Ex-U.K. BMI Growth Index;S&P Developed Ex-U.K. SmallCap Health Care (Sector) Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Over USD5 Billion Index;S&P Developed Ex-Asia-Pacific SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Europe Over USD5 Billion Index;S&P Developed Ex-Europe SmallCap Growth Index;S&P Developed Ex-Eurozone BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia Over USD5 Billion Index;S&P Developed Ex-Australia SmallCap Health Care (Sector) Index;S&P Developed Ex-Canada Over USD5 Billion Index;S&P Developed Over USD5 Billion Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia SmallCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan SmallCap Index;S&P Developed Ex-Switzerland BMI Growth Index;S&P Developed Ex-Switzerland BMI Growth Health Care (Sector) Index;S&P DM Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Growth Index;S&P Developed Ex-Switzerland Over USD5 Billion Index;S&P Developed Ex-Switzerland SmallCap Index;S&P Developed Ex-Switzerland SmallCap Growth Index;S&P Developed Ex-U.K. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed BMI Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Index;S&P Developed Ex-U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Index;S&P Developed Ex-Canada SmallCap Index;S&P Developed Ex-Europe BMI Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P Developed Ex-Japan Over USD5 Billion Index;S&P Global Ex-Japan Over USD5 Billion Index;S&P Global Ex-Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. BMI Index;S&P Global BMI Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia Over USD5 Billion Index;S&P Global Ex-Pan Asia SmallCap Growth Index;S&P Global SmallCap Health Care (Sector) Index;S&P Global SmallCap Index;S&P Global SmallCap Growth Index;S&P North America Over USD5 Billion Index;S&P North America SmallCap Index;S&P North America SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Index;S&P Global Ex-Pan Asia SmallCap Health Care (Sector) Index;S&P Global Over USD5 Billion Index;S&P North America BMI Index;S&P Global SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P United States BMI Index;S&P United States BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America SmallCap Growth Health Care (Sector) Index;S&P North America BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America SmallCap Health Care (Sector) Index;S&P Developed SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global BMI Growth Index;S&P United States BMI Growth Health Care (Sector) Index;S&P United States BMI Health Care (Sector) Index;S&P United States SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P United States Over USD5 Billion Index;S&P Global Ex-Japan BMI Growth Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Growth Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia BMI Growth Index;S&P United States BMI Growth Index;S&P United States SmallCap Growth Index;S&P North America BMI Growth Index;S&P North America BMI Growth Health Care (Sector) Index;S&P North America BMI Health Care (Sector) Index;S&P United States SmallCap Growth Health Care (Sector) Index;S&P United States SmallCap Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Health Care (Sector) Index;S&P Developed Ex-Canada SmallCap Growth Index;S&P DM Ex-Europe SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Growth Index;S&P Developed Ex-U.K. SmallCap Growth Index;S&P Developed SmallCap Growth Index;S&P Developed SmallCap Growth Health Care (Sector) Index;S&P Developed SmallCap Health Care (Sector) Index;S&P Global BMI Health Care (Sector) Index;S&P Global Ex-Japan BMI Index;S&P Global Ex-Japan SmallCap Health Care (Sector) Index;S&P Global Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia SmallCap Index;S&P North America SmallCap Growth Index;S&P United States SmallCap Index;S&P Developed Ex-Japan BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P United States BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P North America BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Canada BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Australia BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P TMI Health Care;S&P Developed Ex-Israel BMI Growth Index;S&P Developed Ex-Israel BMI Growth Health Care (Sector) Index;S&P Developed Ex-Israel BMI Index;S&P Developed Ex-Israel BMI Health Care (Sector) Index;S&P Developed Ex-Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel SmallCap Growth Index;S&P Developed Ex-Israel SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Israel SmallCap Index;S&P Developed Ex-Israel SmallCap Health Care (Sector) Index;S&P DM Ex-Israel SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel Over USD5 Billion Index;S&P Global 1200 - Life Sciences Tools & Services (Industry);S&P Global 1200 - Life Sciences Tools & Services (Sub Ind);S&P Global 1200 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P DM Ex. Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Australia SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P DM Ex-Israel SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Developed Ex-Asia-Pacific SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P DM Ex-Canada SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Europe SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Eurozone SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P United States SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-China A BMI;S&P Global Ex-China A SmallCap;S&P Developed Ex-Korea BMI;S&P Developed Ex-Korea SmallCap;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P North America BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P United States BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Korea BMI Growth;S&P Global 1200 Ex-Canada


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
SAMDI Tech, Inc.
SAMDI Tech, Inc. provides label-free high-throughput screening solutions for drug discovery research. The company was founded in 2011 and is based in Chicago, Illinois. As of January 27, 2023, SAMDI Tech, Inc. operates as a subsidiary of Charles River Laboratories International, Inc.

United States and Canada
Biotechnology
-
-
-
Explora BioLabs Holdings, Inc.
Explora BioLabs Holdings, Inc., a biotechnology company, provides research and consulting services. The company provides in vivo discovery pharmacology and on demand vivarium services to the biotech, pharmaceutical, and academic communities. The company offers research services on pharmacokinetics, toxicology, oncology, metabolic disease, and wound healing. Explora BioLabs Holdings, Inc. was founded in 2004 and is based in San Diego, California with an additional office in Seattle, Washington. As of April 5, 2022, Explora BioLabs Holdings, Inc. operates as a subsidiary of Charles River Laboratories International, Inc.

United States and Canada
Research and Consulting Services
3.00
-
-
Vigene Biosciences, Inc.
Vigene Bioscience Inc. provides viral vector-based gene delivery systems for life science research, gene therapy, and cell therapy applications. It offers adeno-associated virus (AAV) biosensors that are used in vivo injections; Zika virus systems that are used on cells and in vivo research purposes; human cDNA clones; pre-made adenoviral systems; and lentiviral-viral mediated gene delivery systems. The company also provides human microRNA clones and virus systems; AAV shRNA constructs for delivering shRNA plasmids; mammalian expression vectors; and premade control GFP virus. In addition, it offers plasmid cloning, adenoviral cloning, lentiviral cloning, lentiviral packaging, AAV, AAV packaging, nuclease, shRNA cloning, and mutagenesis services. The company serves customers in China, England, the European Union, France, India, Japan, Korea, Switzerland, and Taiwan. It sells its products through distributors, as well as online. Vigene Bioscience Inc. was incorporated in 2012 and is based in Rockville, Maryland. As of June 28, 2021, Vigene Biosciences, Inc. operates as a subsidiary of Charles River Laboratories International, Inc.

United States and Canada
Biotechnology
4.00
-
-
Cognate BioServices, Inc.
Cognate BioServices, Inc., a cell and gene therapy contract development and manufacturing organization (CDMO), provides manufacturing solutions for cell therapies as well as for the production of plasmid DNA and other inputs in the CDMO value chain. It offers development services that include assay development and optimization, process development and optimization, cellular immunotherapy, quality system optimization services, and clinic, regulatory, and custom services. The company also provides manufacturing services that include cGMP cell therapy manufacturing, clinical and commercial manufacturing, custom commercialization and scale-up, viral vector manufacturing, and plasmid DNA manufacturing services; and logistics, supply chain, and manufacturing support. It offers custom development and cGMP manufacturing services to companies across various types of autologous and allogeneic clinical and commercial cell and gene therapy applications in the United States and internationally. Cognate BioServices, Inc. was formerly known as Cognate Therapeutics, Inc. and changed its name to Cognate BioServices, Inc. in June 2006. The company was incorporated in 2002 and is based in Memphis, Tennessee with locations in Baltimore, Maryland; Keele, United Kingdom; and Matfors, Sweden. As of March 29, 2021, Cognate BioServices, Inc. operates as a subsidiary of Charles River Laboratories International, Inc.

United States and Canada
Biotechnology
13.00
-
-
Distributed Bio, Inc.
Distributed Bio, Inc. provides repertoire analysis and engineering solutions to institutions and biotechnology companies. It offers a computational immunology platform for analysis and engineering of antibodies, TCRs, and peptides; a discovery platform that recovers high affinity and drug-worthy antibodies against any target; and an epitope that focuses on vaccine technology to elicit immune responses against specific surfaces. The company was founded in 2010 and is based in South San Francisco, California. As of December 31, 2020, Distributed Bio, Inc. operates as a subsidiary of Charles River Laboratories International, Inc.

United States and Canada
Health Care Technology
-
-
-
Cellero, LLC
Cellero, LLC provides cellular products for cell therapy developers and manufacturers worldwide. Cellero, LLC was incorporated in 2009 and is based in Lowell, Massachusetts. Cellero, LLC operates as a subsidiary of Charles River Laboratories International, Inc.

United States and Canada
Biotechnology
-
-
-
HemaCare Corporation
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, disease-state biospecimens, and cord blood. In addition, the company offers donor recruitment, tissue collection, cell isolation and processing, packaging and shipping, and consulting services. Its network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California. As of January 3, 2020, HemaCare Corporation operates as a subsidiary of Charles River Laboratories International, Inc.

United States and Canada
Health Care Services
35.00
33.00
0.00

Investments as an LP
Forbion Capital Fund III, Forbion Capital Partners B.V.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-30-2023
Jan-27-2023
Merger/Acquisition
Buyer
SAMDI Tech, Inc.
Charles River Laboratories International, Inc. (NYSE:CRL)

50.60
Nov-02-2022
Dec-20-2022
Merger/Acquisition
Seller
Avian Vaccine Business of Charles River Laboratories International, Inc.
Arlington Management Employees, LLC
Charles River Laboratories International, Inc. (NYSE:CRL)
197.30
Jun-13-2022
Jan-26-2023
Private Placement
Buyer
iVexSol Inc.
Casdin Capital, LLC,BioLife Solutions, Inc. (NasdaqCM:BLFS),Bristol-Myers Squibb Company (NYSE:BMY),Charles River Laboratories International, Inc. (NYSE:CRL),Asahi Kasei Medical Co., Ltd.

23.80
May-19-2022
Jan-25-2023
Private Placement
Buyer
Deciphex Limited
ACT Venture Capital Limited,NextSteps Capital,Irrus Investments,Charles River Laboratories International, Inc. (NYSE:CRL),Novartis AG (SWX:NOVN),Hban Medtech Syndicate Nominee Limited,Seroba Life Sciences Limited

16.12
Apr-06-2022
Apr-05-2022
Merger/Acquisition
Buyer
Explora BioLabs Holdings, Inc.
Charles River Laboratories International, Inc. (NYSE:CRL)

291.10
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-10-2023
Company Conference Presentations
Charles River Laboratories International, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-10-2023 11:15 AM
Oct-02-2023
Company Conference Presentations
Charles River Laboratories International, Inc. Presents at 2023 PDA Pharmaceutical Microbiology Conference, Oct-02-2023 12:55 PM
Sep-26-2023
Product-Related Announcements
Charles River Laboratories International, Inc. Unveils Lentivation Platform to Expedite Lvv-Based Gene Therapy Manufacturing
Sep-25-2023
Business Expansions
Charles River Laboratories International, Inc. Announces Opening of RightSourceSM Laboratory
Sep-21-2023
Seeking Acquisitions/Investments
Charles River Laboratories Seeks M&A

Competitors
3M Company (NYSE:MMM), Abcam, Inc., AbCellera Biologics Inc. (NasdaqGS:ABCL), Adimab, LLC, Allele Biotechnology and Pharmaceuticals, Inc., Alliance Pharma plc (AIM:APH), ALS Minerals, Inc., Anupam Rasayan India Ltd (NSEI:ANURAS), Applus Services, S.A. (BME:APPS), Avid Bioservices, Inc. (NasdaqCM:CDMO), Becton, Dickinson and Company (NYSE:BDX), bioMérieux S.A. (ENXTPA:BIM), Boston Analytical, Inc., Bureau Veritas SA (ENXTPA:BVI), Cambrex Corporation, Catalent, Inc. (NYSE:CTLT), Chiltern International Limited, Distributed Bio, Inc., Emergent BioSolutions Inc. (NYSE:EBS), Endo International plc (OTCPK:ENDP.Q), Envigo RMS, Inc., Ergomed plc (AIM:ERGO), Eurofins Agroscience Services Limited, Eurofins Scientific SE (ENXTPA:ERF), Evotec SE (XTRA:EVT), Fate Therapeutics, Inc. (NasdaqGM:FATE), Frontage Holdings Corporation (SEHK:1521), FUJIFILM Diosynth Biotechnologies U.S.A., Inc., FUJIFILM Holdings Corporation (TSE:4901), Icon Limited, ICON Public Limited Company (NasdaqGS:ICLR), Intertek Group plc (LSE:ITRK), IQVIA Holdings Inc. (NYSE:IQV), KBI Biopharma, Inc., Labcorp Drug Development Inc., Laboratory Corporation of America Holdings (NYSE:LH), Lonza Group AG (SWX:LONN), Medelis, Inc., Merck Millipore Limited, Metrion Biosciences Ltd, OmniAb, Inc. (NasdaqGM:OABI), Pace Analytical Services, LLC, Parexel International Corporation, Patheon Inc., Perrigo Company plc (NYSE:PRGO), Pharmaceutical Product Development, LLC, Pharmaron, Inc., PRA Health Sciences, Inc., Protea Biosciences Group, Inc, Quest Diagnostics Incorporated (NYSE:DGX), Rapid Micro Biosystems, Inc. (NasdaqGS:RPID), ReproCELL Incorporated (TSE:4978), SCM Lifescience Co., Ltd. (KOSDAQ:A298060), Selvita S.A. (WSE:SLV), SGS SA (SWX:SGSN), Syneos Health, Inc., Taconic Biosciences, Inc., Takeda Pharmaceutical Company Limited (TSE:4502), Thermo Fisher Scientific Inc. (NYSE:TMO), Twist Bioscience Corporation (NasdaqGS:TWST), Vetter Pharma-Fertigung GmbH & Co. KG, Viva Biotech Holdings (SEHK:1873), WuXi AppTec Co., Ltd. (SHSE:603259), WuXi AppTec, Inc., WuXi Biologics (Cayman) Inc. (SEHK:2269)

M&A Advisors
Axinn, Veltrop & Harkrider LLP, BofA Securities, Inc., Cooley LLP, Credit Suisse AG, Credit Suisse Securities (USA) LLC, Davis Polk & Wardwell LLP, DLA Piper UK LLP Shanghai Representative Office, Gibson, Dunn & Crutcher LLP, Gordon Dyal & Co. Advisory Group LP, Hannes Snellman Attorneys Ltd, Hengeler Mueller Partnerschaft von Rechtsanwälten mbB, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Morgan Stanley (NYSE:MS), Morrison & Foerster LLP (Japan), Nixon Peabody LLP, O'Melveny & Myers LLP, Weil, Gotshal & Manges LLP, Wells Fargo Securities, LLC


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Axinn, Veltrop & Harkrider LLP, BofA Securities, Inc., Cooley LLP, Credit Suisse AG, Credit Suisse Securities (USA) LLC, Davis Polk & Wardwell LLP, DLA Piper UK LLP Shanghai Representative Office, Gibson, Dunn & Crutcher LLP, Gordon Dyal & Co. Advisory Group LP, Hannes Snellman Attorneys Ltd, Hengeler Mueller Partnerschaft von Rechtsanwälten mbB, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Morgan Stanley (NYSE:MS), Morrison & Foerster LLP (Japan), Nixon Peabody LLP, O'Melveny & Myers LLP, Weil, Gotshal & Manges LLP, Wells Fargo Securities, LLC
Public Offering Advisors
Davis Polk & Wardwell LLP, PricewaterhouseCoopers LLP, Ropes & Gray LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
The Economy Matters

Oct 08, 2023 10:36 PM
CRL
The Economy Matters
Reports
8
CFRA Equity Research
Hardy, Sel
Oct 07, 2023 04:19 PM
CRL
Charles River Laboratories International, Inc.
Reports
9
New Constructs, LLC

Oct 06, 2023 08:11 PM
CRL
CRL: Forensic Stock Earnings & Valuation
Reports
6
GlobalData

Oct 06, 2023 06:07 AM
CRL
Charles River Laboratories International Inc (CRL.XNYS) - Medical Equipment - Deals and Alliances Profile
Reports
78
S&P Global Compustat

Oct 05, 2023 03:12 AM
CRL
Charles River Laboratories International Inc 2023_10_05
Reports
17
GlobalData

Oct 05, 2023 01:50 AM
CRL
Charles River Laboratories International Inc (CRL.XNYS) - Financial and Strategic SWOT Analysis Review
Reports
271
Zacks Investment Research Inc.

Oct 04, 2023 08:31 AM
CRL
Charles River Laboratories International, Inc(CRL) Zacks Company Report
Reports
9
ValuEngine, Inc.

Oct 02, 2023 03:40 AM
CRL
ValuEngine Rating and Forecast Report for CRL
Reports
11
CFRA Equity Research
Hardy, Sel
Sep 30, 2023 04:14 PM
CRL
Charles River Laboratories International, Inc.
Reports
9
MarketLine

Sep 30, 2023 06:01 AM
CRL
Charles River Laboratories International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
283


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


The Vanguard Group, Inc.

5,924,378

11.55

1,554.8

Jun-30-2023


BlackRock, Inc.

5,198,037

10.14

1,364.2

Jun-30-2023


T. Rowe Price Group, Inc.

2,496,494

4.87

655.2

Jun-30-2023


State Street Global Advisors, Inc.

2,091,017

4.08

548.8

Jun-30-2023


ClearBridge Investments, LLC

1,750,110

3.41

459.3

Jun-30-2023


Kayne Anderson Rudnick Investment Management, LLC

1,681,120

3.28

441.2

Jun-30-2023


Allspring Global Investments, LLC

1,188,828

2.32

312.0

Jun-30-2023


Geode Capital Management, LLC

1,101,400

2.15

289.1

Jun-30-2023


Ariel Investments, LLC

1,047,840

2.04

275.0

Jun-30-2023


Mackenzie Financial Corporation

919,142

1.79

241.2

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
BlackRock, Inc.
5,198,037
411,153
Ariel Investments, LLC
1,047,840
364,786
ClearBridge Investments, LLC
1,750,110
343,076
Point72 Asset Management, L.P.
325,706
288,889
Montrusco Bolton Investments Inc.
629,825
219,637

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Marshall Wace LLP
426,526
(528,388)
Viking Global Investors LP
0
(394,089)
Jackson Square Partners, LLC
591,241
(312,726)
William Blair Investment Management, LLC
398,187
(301,890)
Fred Alger Management, LLC
15,872
(221,629)


S&P Global Ratings Credit Ratings
Debt Type (Rating Type)
Current Rating
Rating Date
Current CreditWatch / Outlook
Current CreditWatch / Outlook Date
Issuer Credit Rating (Local Currency LT)
BB+
May-01-2019
Stable
5/1/2019 5:32:18 PM
Issuer Credit Rating (Foreign Currency LT)
BB+
May-01-2019
Stable
5/1/2019 5:32:18 PM


News Headlines
Date/Time
Headline
Source
Sep-15
Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
ENP Newswire
Sep-15
The Future of Medicine Rises in University City: University of Pennsylvania Opens New Multi-Disciplinary Research Labs in One uCity Square
India Pharma News
Sep-12
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
ENP Newswire


Company Coverage
This company is not on any Coverage List.

Products
360 Diagnostics, 5-batch Analysis Services, AccuFUN-ID, Accugenix, Accugenix Microbial ID & Strain Typing Services, Accugenix Sample Submission Services, ADME/QWDA Study Services, Agrochemical Development Services, Allogeneic Cell Therapy Drug Products, Analytical Characterization Services, Animal Health Product Development Services, Antibody Production Services, Apollo, Archival Services, Archiving/Repository, Avian Antigens & Antisera Services, Avian Diagnostic & Regulatory Testing Services, Bioanalysis Services, Biocide Development Services, Biologics Testing Services, Biomechanical Strength Testing Services, Biotransformation Services, Bone and Joint Research Services, Bone Research Services, Cardiac Risk Assessment Services, Cell Banks, Cell Line & Protein Characterization Services, Celsis Accel, Celsis Adapt, Celsis Advance II, Celsis Advantage, Celsis Complete, Celsis for Sterility, Celsis Microbial Detection, cGMP Manufacturing Services, Chemical Development & REACH Services, Chemicals, Agro & Vet Services, Chicken Cell Products, Clinical Field Studies, Clinical Trial Management Services, Clinical Trial Vaccines, Contract Endotoxin Testing Services, Customer & Technical Support Solutions, Diagnostic and Quantitative Imaging Services, Discovery Assay Development and Screening Services, Distribution of SPF Fertile Chicken Eggs, Distribution of SPF Fertile Chickens, DMPK and Non-GLP Toxicology Services, Drug Metabolism and Pharmacokinetics Services, Early Discovery Services, Ecotoxicology Studies, Efficacy Testing Services, Endosafe nexgen-PTS, Endosafe-MCS, Endosafe-Nexus, Endosafe-PTS, EndoScan-V, Endotoxin Test Kits, Endotoxin Testing Accessories, Endotoxin Testing Instruments and Services, Endotoxin Testing Reagents, Endotoxin Testing Services, Endotoxin Testing Software, Environmental Fate Studies, Environmental Risk Assessment Service, Environmental Sciences Services, EXpDNA Plasmid Platform, Field Trials Services, Formulation and Analytical Chemistry Services, Genetic Testing Services, Genetically Engineered Models and Services, HCP ELISA Kit, Health Reports, Histomorphometry Services, Horseshoe Crab Conservation Solutions, Human Influenza & Sendai Viruses, Human-Derived Cellular Materials, Immuno-Oncology Assays Services, Immunology and Immunotoxicology Services, In Vitro and In Vivo Studies Services, In Vitro Pharmacology Services, In Vivo and In Vitro Discovery Services, IND-Enabling Studies Services, Influenza & Sendai Viruses Vaccine Services, Insourcing Solutions, Kinetic Instrumentation & Software, Lab Sciences Services, Laboratory Services, Laboratory Support Services, LAL Testing Services, Livestock Feeding Studies, Lot Release and Safety Testing Support Services, Lot-release Testing Products, Maintenance and Monitoring Services, Mechanism of Action Studies Services, Metabolite Profiling & Identification Services, Microbial Detection and Identification Kits, Mycoplasma & Pullorum Plate Antigens Services, Novel Biomarker ID and Assay Development Services, Optimization Plus In Vitro and In Vivo Studies Services, Pathology Services, Pharmaceutical Sciences & Formulation Services, Physicochemical Studies, Plant Metabolism Services, Poultry Diagnostics and Antigens, Preconditioning Services, Process Chemistry Services, Program Management Services, PTS-Micro, Quality Control Test Reagents, Quality Control Testing Services, Quality Management Solutions, Radioanalysis Services, Reagents and Instruments, Research Animal Diagnostic Services, Research Models, Residue Studies, RightSource, Rodent Surgery Services, Safety Pharmacology Services, Scientific & Regulatory Advisory Services, Skin Penetration, Software and Accessories, Species Identification Services, Stability Testing Services, Standard for Exchange of Nonclinical Data, Sterility and Microbial Limits Rest Kits, Strategic Non-clinical Consulting Services, Strategic Preclinical Consulting Services, Structural Biology & Biophysics Services, Surgical Models, Synthetic and Medicinal Services, The Celsis Approach, Therapeutic Discovery Services, Toxicology Services, Transgenic Models, Transgenic Services, Translational Tools, Tumor Model Compendium Web Interface, Vaccine and Vector Safety Services, Vaccine Support Products, Viral Clearance Services, Virology Services


Upcoming Events
Date/Time
Type
Nov-01-2023
Estimated Earnings Release Date (S&P Global Derived)
Nov-12-2023
Conferences
Nov-14-2023
Conferences
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-09-2023
Jul-01-2023
Charles River Laboratories International, Inc. (NYSE:CRL)
SEC
10-Q
8 MB
Aug-09-2023
Aug-09-2023
Charles River Laboratories International, Inc. (NYSE:CRL)
SEC
8-K (2.02, 9.01)
838 KB
May-15-2023
May-15-2023
Charles River Laboratories International, Inc. (NYSE:CRL)
SEC
8-K (5.07)
191 KB
May-11-2023
Apr-01-2023
Charles River Laboratories International, Inc. (NYSE:CRL)
SEC
10-Q
9 MB
May-11-2023
May-11-2023
Charles River Laboratories International, Inc. (NYSE:CRL)
SEC
8-K (2.02, 9.01)
576 KB
May-01-2023
-
Charles River Laboratories International, Inc. (NYSE:CRL)
SEC
DEFA14A
23 KB
Mar-30-2023
-
Charles River Laboratories International, Inc. (NYSE:CRL)
SEC
DEF 14A
11 MB
Feb-22-2023
Dec-31-2022
Charles River Laboratories International, Inc. (NYSE:CRL)
SEC
10-K
17 MB
Feb-22-2023
Feb-22-2023
Charles River Laboratories International, Inc. (NYSE:CRL)
SEC
8-K (2.02, 9.01)
766 KB
Dec-06-2022
Dec-05-2022
Charles River Laboratories International, Inc. (NYSE:CRL)
SEC
8-K (5.02)
168 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Wallman, Richard F. (Independent Director)
Aug-24-2023
Common Stock
1,000
270,375
Open Market Acquisition
4.57
Form 4
Foster J.D., James C. (Chairman, CEO & President)
Aug-10-2023
Common Stock
(2,500)
0
Other Disposition
(0.99)
Form 4
Barbo, William D. (Chief Commercial Officer & Corporate Executive VP)
Aug-10-2023
Common Stock
(5,763)
(1,702,820)
Open Market Disposition
(18.92)
Form 4
Barbo, William D. (Chief Commercial Officer & Corporate Executive VP)
Aug-10-2023
Common Stock
5,511
1,084,400
Derivative Exercise and Retained Stock
28.72
Form 4
Knell, Michael Gunnar (Corporate Senior VP & Chief Accounting Officer)
Aug-10-2023
Common Stock
(1,471)
(143,794)
Derivative Exercise and Sale
-
Form 4
-
Aug-10-2023
Common Stock
1,471
289,449
Derivative Exercise
-
Form 4
-
Aug-10-2023
Common Stock
(1,471)
(433,243)
Sale
-
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Foster, James C.
Chairman, CEO & President
781 222 6000
-

Kochevar, Deborah T.
Independent Director
781 222 6000
-

Reese, C. Richard
Independent Director
781 222 6000
-

Wallman, Richard F.
Independent Director
781 222 6000
-

Wilson, Virginia Mary
Independent Director
781 222 6000
-

Massaro, George E.
Lead Independent Director
781 222 6000
-

Andrews, Nancy C.
Independent Director
781 222 6000
-

Bertolini, Robert J.
Independent Director
781 222 6000
-

Llado, George 
Independent Director
781 222 6000
-

MacKay, Martin W.
Director
781 222 6000
-

Thompson, Craig B.
Independent Director
781 222 6000
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Foster, James C.
Chairman, CEO & President
781 222 6000
-

Pease, Flavia H.
Corporate Executive VP & CFO
781 222 6000
-

Girshick, Birgit 
Corporate Executive VP & COO
781 222 6000
-

Knell, Michael Gunnar
Corporate Senior VP & Chief Accounting Officer
781 222 6000
-

Frearson, Julie 
Corporate Senior VP & Chief Scientific Officer
781 222 6000
-

Mintz, Mark 
Corporate Senior VP & Chief Information Officer
781 222 6000
-

Spencer, Todd 
Corporate Vice President of Investor Relations
(781) 222-6455
-
todd.spencer@crl.com
Daniel, Matthew L.
Corporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer
781 222 6000
-

Cianciaruso, Amy 
Corporate Vice President & Chief Communications Officer
(781) 222-6168
-
amy.cianciaruso@crl.com
Eisenhauer, Kristen M.
Corporate Senior Vice President of Client Services & Sales
781 222 6000
-

LaPlume, Joseph W.
Corporate Executive Vice President of Corporate Development & Strategy
781 222 6000
-

Mullane, Gina M.
Chief Marketing Officer & Corporate Senior VP
781 222 6000
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
